CTLA4 and melanoma: For example, the combination of moDCs with anti-CTLA4 blockade in advanced melanoma patients showed an encouraging response rate of 38%, with all complete responders (n = 7) still free from progression and off-therapy more than 5 years after the initiation of DC therapy [30].